XML 40 R12.htm IDEA: XBRL DOCUMENT
v3.19.3

REVENUES | 9 Months Ended
--- | ---
Sep. 30, 2019
REVENUES |
REVENUES | NOTE 5 – REVENUES The following table summarizes the Company’s disaggregation of revenues:
|  | Nine Months Ended September 30,
(U.S. dollars in thousands) |  |  | 2019 |  |  | 2018
Pfizer |  | $ | 4,701 |  | $ | 4,649
Brazil |  | $ | 7,385 |  | $ | 2,573
Total revenues from selling goods |  | $ | 12,086 |  | $ | 7,222
Revenues from license and R&D services |  | $ | 24,848 |  | $ | 16,665
The following table sets forth data regarding the Company’s contracts liability:
|  | Nine Months Ended September 30,
(U.S. dollars in thousands) |  | 2019 |  | 2018
Contracts liability at the beginning of the period |  | $ | 42,895 |  | $ | 25,015
Additions during the period |  |  | 22,151 |  |  | 34,929
Revenue recognized during the period |  |  | (24,848) |  |  | (16,665)
Contracts liability at the end of the period |  | $ | 40,198 |  | $ | 43,279
The following table represents the Company’s unsatisfied performance obligation:
|  | September 30,
(U.S. dollars in thousands) |  | 2019 |  | 2018
Unsatisfied performance obligation |  | $ | 50,584 |  | $ | 76,969

X
- Definition The entire disclosure pertaining to revenue. + References No definition available. + Details
Name: | plx_RevenueDisclosureTextBlock
Namespace Prefix: | plx_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueRecognitionAndDeferredRevenueAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration